Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial

Objective To evaluate the use of routine laboratory monitoring in terms of clinical outcomes among patients receiving antiretroviral therapy (ART) in Uganda. Design Randomised clinical trial Setting A home based ART programme in rural Uganda. Participants All participants were people with HIV who were members of the AIDS Support Organisation. Participants had CD4 cell counts <250 cells × 106/L or World Health Organization stage 3 or 4 disease. Interventions Participants were randomised to one of three different monitoring arms: a viral load arm (clinical monitoring, quarterly CD4 counts, and viral load measurements), CD4 arm (clinical monitoring and CD4 counts), or clinical arm (clinical monitoring alone). Main outcome measures Serious morbidity (newly diagnosed AIDS defining illness) and mortality. Results 1094 participants started ART; median CD4 count at baseline was 129 cells × 106/L. Median follow-up was three years. In total, 126 participants died (12%), 148 (14%) experienced new AIDS defining illnesses, and 61(6%) experienced virological failure, defined as two consecutive viral loads >500 copies/mL occurring more than three months after the start of ART. After adjustment for age, sex, baseline CD4 count, viral load, and body mass index, the rate of new AIDS defining events or death was higher in the clinical arm than the viral load arm (adjusted hazard ratio 1.83, P=0.002) or the CD4 arm (1.49, P=0.032). There was no significant difference between the CD4 arm and the viral load arm (1.23, P=0.31). Conclusion In patients receiving ART for HIV infection in Uganda, routine laboratory monitoring is associated with improved health and survival compared with clinical monitoring alone. Trial registration Clinical Trials NCT00119093.

[1]  Summary TOWARDS UNIVERSAL ACCESS : Scaling up Priority HIV / AIDS Interventions in the Health Sector Progress Report , 2008 .

[2]  M. Hirsch,et al.  Monitoring HIV treatment in developing countries , 2006, BMJ : British Medical Journal.

[3]  Mark Dybul,et al.  Rapid expansion of the health workforce in response to the HIV epidemic. , 2007, The New England journal of medicine.

[4]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[5]  T. Quinn,et al.  Predictors of Long-Term Viral Failure Among Ugandan Children and Adults Treated With Antiretroviral Therapy , 2007, Journal of acquired immune deficiency syndromes.

[6]  R. Chaisson,et al.  Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  N. Ford,et al.  HIV viral load monitoring in resource-limited regions: optional or necessary? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  E. Nicastri,et al.  Clinical outcome after 4 years follow‐up of HIV‐seropositive subjects with incomplete virologic or immunologic response to HAART , 2005, Journal of medical virology.

[9]  T. Quinn,et al.  Two-Year Virologic Outcomes of an Alternative AIDS Care Model: Evaluation of a Peer Health Worker and Nurse-Staffed Community-Based Program in Uganda , 2009, Journal of acquired immune deficiency syndromes.

[10]  J. Tappero,et al.  Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study , 2008, The Lancet.

[11]  A. Harries,et al.  Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi , 2008, Tropical medicine & international health : TM & IH.

[12]  A. Phillips,et al.  Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. , 2008, The Journal of infectious diseases.

[13]  B. Yip,et al.  Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated With Increased Mortality and Poor Adherence to Therapy , 2005, Journal of acquired immune deficiency syndromes.

[14]  N. Parkin,et al.  The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.

[15]  B. Yip,et al.  Performance of Immunologic Responses in Predicting Viral Load Suppression: Implications for Monitoring Patients in Resource-Limited Settings , 2006, Journal of acquired immune deficiency syndromes.

[16]  A. Breckenridge,et al.  Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial , 2010, The Lancet.

[17]  Wasun Chantratita,et al.  Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Tze Leung Lai,et al.  Modified Haybittle–Peto group sequential designs for testing superiority and non‐inferiority hypotheses in clinical trials , 2006, Statistics in medicine.

[19]  Ross J. Harris,et al.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.

[20]  A. Wensing,et al.  Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. , 2010, The Lancet. Infectious diseases.

[21]  P. Kaleebu,et al.  Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa , 2006, AIDS.

[22]  K. Anastos,et al.  Antiretroviral therapy in resource‐limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub‐Saharan Africa, Asia and Latin America , 2008, Tropical medicine & international health : TM & IH.

[23]  K. Buchacz,et al.  Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda , 2006, The Lancet.

[24]  N. Ford,et al.  Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. , 2007, The Journal of infectious diseases.

[25]  A. Westfall,et al.  Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  P. Weidle,et al.  Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance , 2002, The Lancet.

[27]  H. Sørensen,et al.  Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. , 2006, Clinical Infectious Diseases.

[28]  B. Chi,et al.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. , 2006, JAMA.

[29]  N. Ford,et al.  Scaling up antiretroviral treatment in resource-poor settings , 2006, The Lancet.

[30]  Sydney Rosen,et al.  Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review , 2007, PLoS medicine.

[31]  Kara Wools-Kaloustian,et al.  Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya , 2006, AIDS.

[32]  R. Rodrigues,et al.  CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: partial control of viremia is associated with favorable outcome. , 2004, AIDS patient care and STDs.

[33]  N. Kumarasamy,et al.  Generic antiretroviral drugs—will they be the answer to HIV in the developing world? , 2004, The Lancet.

[34]  P. Farmer,et al.  Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience , 2004, AIDS.

[35]  Deenan Pillay,et al.  Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model , 2008, The Lancet.

[36]  Richard L. Degerman,et al.  CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study , 2011, BMJ : British Medical Journal.

[37]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[38]  T. Quinn,et al.  Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda , 2009, AIDS.

[39]  R. Stone,et al.  Discordant Responses to Potent Antiretroviral Treatment in Previously Naive HIV-1-Infected Adults Initiating Treatment in Resource-Constrained Countries: The Antiretroviral Therapy in Low-Income Countries (ART-LINC) Collaboration , 2007, Journal of acquired immune deficiency syndromes.

[40]  B. Strom,et al.  Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy , 2006, AIDS.

[41]  M. Dybul,et al.  Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda , 2009, Antiviral therapy.

[42]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[43]  N. Ford,et al.  Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.